Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is Chief of Clinical Trials, Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Centre Tom Powles is Director of Barts Cancer Centre, St Bartholomews Hospital and Professor or Genitourinary oncology, Queen Mary University of London
…
continue reading
腎がんの最新の話題〜IO rechallengeと乳頭型腎がんの治療戦略〜
…
continue reading
前立腺がんの最新の話題〜T cell directed therapyとradioligands〜
…
continue reading
膀胱がんの最新の話題〜周術期薬物療法とADC〜
…
continue reading
Betrand Tombal joins Brian and Tom to discuss the historic and current data for AR inhibition with monotherapy with AR blockers.
…
continue reading
Christopher Cutie from J&J joins the show to discuss the SUNRISE bladder program with the gemcitabine-eluting pretzel across several NMIBC and MIBC states.
…
continue reading
The RCC panel at Uromigos Live 2024 discusses and debates this topic.
…
continue reading
Eneste podcast cubrimos los temas de cáncer urotelial discutidos por los Uromigos. El impacto del estudio NIAGARA en utiliar quimio más inmunoterapia enneadyuvancia de Ca urotelial músculo invasor, el uso de pembrolizumab adyuvante después de los datos del estudio AMBASSADOR y la búsqueda de biomarcadores.…
…
continue reading
1
Episode 357: #UromigosLive24 - Peri-operative Therapy in Bladder Cancer
1:03:10
1:03:10
در پخش در آینده
در پخش در آینده
لیست ها
پسندیدن
دوست داشته شد
1:03:10
Tom leads a panel of Shilpa Gupta, Andrea Apolo, Kala Sridhar and Petros Grivas to discuss and debate this timely topic.
…
continue reading
Brian moderates the panel that discusses and debates TKI, vs Ipi/Nivo vs IO/TKI
…
continue reading
The Uromigos Live 2024 panel discusses recent radioligand data including PEACE-3
…
continue reading
Brian hosts a panel at Uromigos Live 2024 in Nashville with Michael Morris, Tanya Dorff and Karen Autio
…
continue reading
Tom moderates a live panel of Kala Sridhar, Shilpa Gupta, Andrea Apolo and Petros Grivas on the emerging ADC data in bladder cancer
…
continue reading
Tom and Brian finish discussing ESMO 2024 highlights. Even without a guest Tom still interrupts a lot.
…
continue reading
Silke joins us to discuss ESMO 2024 highlights, then the birds start singing....
…
continue reading
Fresh of the Presidential session address, Tom discusses his data with Petros commenting.
…
continue reading
Uromigos Japan with Yuji, Hiroshi and Nobu is formed and discuss Hiroshi's ESMO data.
…
continue reading
Arun Azad describes this randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC
…
continue reading
Matt Galsky describes his ESMO 2024 abstract of disitimab vedotiin + pembrlizumab in bladder cancer
…
continue reading
Silke Gillessen joins us to discuss her Presidential session from ESMO 2024
…
continue reading
Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC
…
continue reading
Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC
…
continue reading
Katy Beckermann discusses the TiNivo-2 study presented at ESMO 2024.
…
continue reading
Silke joins Brian and Tom to discuss upcoming data in prostate, bladder and kidney cancer in Barcelona at ESMO 2024
…
continue reading
Nima Sharifi joins Brian and Tom to discuss mechanisms of resistance to hormone therapy in prostate cancer
…
continue reading
Ira Mellman delves into the update of this classic paper and the components of an effective anti-tumor immune response.
…
continue reading
María, Christina y Elena analizan los cambios recientes en las directrices de la ESMO en el cáncer de riñón, vejiga y próstata.
…
continue reading
Naomi Haas joins Tom and Brian in New York City at the World GU Conference to discuss several RCC topics
…
continue reading
Eric Jonasch, Co-Chair of the NCCN RCC Guidelines, gives insight into the process of guideline modification and discusses updates in adjuvant, front-line and refractory RCC
…
continue reading
Jonathan Rosenberg and a surprise guest discuss comorbidities and treatment-related side effects.
…
continue reading
David Braun divides immune therapies into four groups and describes how novel treatments and targets work. Tom and Brian are both excited and, at times, sceptical.
…
continue reading
Escuche nuestro primer podcast sobre los aspectos más destacados de ASCO en cáncer de vejiga, riñón y próstata
…
continue reading
Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden answer a range of relevant and sometimes irrelevant questions
…
continue reading
Viktor Gruenwald, Boris Hadaschik and Gunhild Von Amsberg answer questions around GU cancer and German football
…
continue reading
Aditya Bagrodia describes three new drugs/studies in NMIBC.
…
continue reading
Silke Gillessen joins Tom and Brian, who give their opinion on the data and new 'Take Home Message' format.
…
continue reading
Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura battle through the sometimes ridiculous questions set by Tom and Brian.
…
continue reading
1
Episode 328 ASCO24: Emergency podcast - what the NADINA trial means for preoperative GU cancer studies
26:32
David McDermott discusses the adjuvant vs neoadjuvant immune therapy trial and its wider implications.
…
continue reading
Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node only 1st line UC patients. Tom describes the QOL data for EV pembro.
…
continue reading
Laurence Albiges discusses this circulating biomarker which may be predictive and prognostic.
…
continue reading
Toni Choueiri and Brian describe similarities and differences in the biomarker findings of these two trials. Debate about the value and future of this approach breaks out.
…
continue reading
Andrea Necchi gives us the lowdown of efficacy and toxicity of this combination.
…
continue reading
Jonathan Rosenberg gets to grips with the data available for the bladder cohort from the TDXD Destiny pan-tumour cohort.
…
continue reading
Alex Wyatt describes the predictive resistance of ctDNA fraction at baseline in predicting outcome.
…
continue reading
Christos Kyriakopoulos describes the outcome of this study, where cabazitaxel with abiraterone as combined with abiraterone alone in docetaxel refractory CRPC.
…
continue reading
Danny Heng, Christian Kollmannsberger and Kala Sridhar answer questions in an attempt to get to Nashville and take on LA to win the Uromigos Cup.
…
continue reading
What to see at the ASCO 2024 Annual Meeting, with Silke Gillessen.
…
continue reading
Nick James discusses this paper, which covers broad issues in prostate cancer - including diagnosis and treatment with a focus on the future.
…
continue reading
David Penson discusses highlights for the upcoming meeting. He articulates his excitement around the NMIBC data.
…
continue reading
Silke covers key aspects of the meeting, including surgery vs RT, genetic and somatic testing, PSMA imaging and 1st line triplet therapy.
…
continue reading
1
Episode 315: APCCC 2024 Quickfire - Bone health, hot flashes and gynecomastia in prostate cancer
18:17
Chris Sweeney is joined by Matt Smith, Anthony Joshua and Lisa Horvath to discuss the management of these complex issues in advanced prostate cancer.
…
continue reading